Cryofocus Medtech (Shanghai) Co (HKSE:06922) EBIT : HK$-114.95 Mil (TTM As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co EBIT?

Cryofocus Medtech (Shanghai) Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was HK$-51.51 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-114.95 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cryofocus Medtech (Shanghai) Co's annualized ROC % for the quarter that ended in Jun. 2023 was -151.31%. Cryofocus Medtech (Shanghai) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -224.06%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cryofocus Medtech (Shanghai) Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -4.06%.

Cryofocus Medtech (Shanghai) Co EBIT Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryofocus Medtech (Shanghai) Co EBIT Chart

Cryofocus Medtech (Shanghai) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-188.83

-154.43

-131.47

-114.95

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial			-	-52.26	-81.69	-51.51	-63.44

Competitive Comparison of Cryofocus Medtech (Shanghai) Co's EBIT

For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cryofocus Medtech (Shanghai) Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's EV-to-EBIT falls into.

Cryofocus Medtech (Shanghai) Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-114.95 Mil.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cryofocus Medtech (Shanghai) Co's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-111.514 * ( 1 - 0% )	/	( (62.928	+	84.466)	/ 2 )
=	-111.514	/	73.697
=	-151.31 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	350.495	-	43.594	-	( 252.849	-	max(0, 51.072	-	295.045	+	252.849	))
=	62.928

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	280.749	-	22.357	-	( 173.926	-	max(0, 28.519	-	228.942	+	173.926	))
=	84.466

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Cryofocus Medtech (Shanghai) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-103.022	/	( ( (46.635 + max(-24.985, 0))	+	(43.274 + max(2.049, 0)) )	/	2 )
=	-103.022	/	( ( 46.635	+	45.323 )	/	2 )
=	-103.022	/	45.979
=	-224.06 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	22.254	+	5.6843418860808E-14)	-	(43.594	+	0	+	3.645)
=	-24.985

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.021	+	27.525	+	2.8421709430404E-14)	-	(22.357	+	0	+	3.14)
=	2.049

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cryofocus Medtech (Shanghai) Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-114.951	/	2831.666
	=	-4.06 %

Cryofocus Medtech (Shanghai) Co EBIT Related Terms

Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, CHN, 200120

Website

https://www.cryofocus.com

Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture and sale of cryoablation minimally-invasive interventional treatment technology and related medical products. It has two Core Products, the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Bladder Cryoablation System is a cryotherapy device designed for the treatment of bladder cancer. The Endoscopic Clip for Anastomosis is an anastomotic device for the closure of soft tissue in the digestive tract, which is one of the over-the-scope clips. Geographically company's key revenue is generated from China.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Headlines

No Headlines